A joint bid by drugmaker UCB and five other UK-based groups has won the Government’s 2014 Advanced Manufacturing Supply Chain Initiative, picking up a £6.2 million grant to fine tune the development of novel biologics.

Patients should “benefit substantially” from new approaches to addressing disease and through the streamlining of the development process for biologics, “which has the potential to deliver greater efficiencies, lower costs and better quality of treatments,” UCB noted.

UCB and Lonza Biologics are heading up the consortium, and are joined by specialist biotechs Sphere Fluidics, Horizon Discovery and Alcyomics, who will contribute with their expertise in microfluidic single cell analysis, gene editing technology and preclinical safety analysis.

The consortium will also leverage in-kind contributions from each member to take the total investment to over £11 million.